^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Cdactin-O (CBM588)

    i
    Other names: CBM588, CBM-588, clostridium butyricum Miyairi 588 strain, CM588
    Associations

    News

    Trials
    Company:
    Miyarisan, Osel
    Drug class:
    Microbiome modulator
    Related drugs:
    Associations

    News

    Trials
    1d
    Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (clinicaltrials.gov)
    P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Jan 2027
    Enrollment open • Trial initiation date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Keytruda (pembrolizumab) • Cdactin-O (CBM588)
    1m
    Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Cdactin-O (CBM588) • zanzalintinib (XL092)
    1m
    Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (clinicaltrials.gov)
    P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> Oct 2028 | Trial primary completion date: May 2027 --> Oct 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Keytruda (pembrolizumab) • Cdactin-O (CBM588)
    2ms
    A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer. (PubMed, Front Immunol)
    The probiotic Clostridium butyricum strain MIYAIRI 588 (CBM588) improves response rates and overall survival in patients receiving immune checkpoint inhibitor (ICI) therapy for non-small cell lung cancer and metastatic renal cell carcinoma but the mechanism underlying this benefit remains unclear...Across the patient cohort, higher post-treatment frequencies of CD69+ Vδ2 T-cells were associated with improved survival and more favourable clinical outcomes. These findings provide a potential mechanism by which manipulation of the intestinal microflora might contribute to cancer prognosis through effects on immune effector cells with intrinsic anticancer properties.
    Journal • IO biomarker
    |
    CD69 (CD69 Molecule)
    |
    Cdactin-O (CBM588)
    2ms
    MIYAIRI 588: CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Cdactin-O (CBM588)
    3ms
    Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC (clinicaltrials.gov)
    P2, N=146, Not yet recruiting, chenxu
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • Cdactin-O (CBM588)
    3ms
    CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Cdactin-O (CBM588)
    4ms
    PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum) (clinicaltrials.gov)
    P=N/A, N=158, Not yet recruiting, Casa di Cura Dott. Pederzoli
    New trial
    |
    Cdactin-O (CBM588)
    4ms
    Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (clinicaltrials.gov)
    P3, N=718, Not yet recruiting, SWOG Cancer Research Network
    New P3 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • axitinib • ABP 206 (nivolumab biosimilar) • Cdactin-O (CBM588) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    6ms
    CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Cdactin-O (CBM588)
    12ms
    Effect of Clostridium butyricum and antibiotics using simultaneous simple suspension in mice with Clostridioides difficile infection. (PubMed, Exp Mol Pathol)
    This study using mice demonstrates the effectiveness of simultaneous simple suspensions of CBM and antibiotics in treating CDI. This approach significantly reduces C. difficile counts, modulates cytokine levels, and maintains probiotic viability, potentially making it a viable option for administration via gastric tubes in clinical settings.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    Cdactin-O (CBM588)
    12ms
    Adding a Probiotic (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery (clinicaltrials.gov)
    P2, N=62, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Keytruda (pembrolizumab) • Cdactin-O (CBM588)